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The interplay between cancerous cells and immune cells has always
been an intriguing topic in medicine and biology. Cancer cells
emerge from self-cells through a series of genetic mutations. They
often retain self-cells’ capacity in being exempt from immune sur-
veillance. Therefore, bringing cancer cells back under the radar
of immune system has long been considered as a necessary step
toward complete tumor eradication and long-term antitumor pro-
tection. Based on this rationale, a series of immunotherapies were
designed and many have shown promising results. Some have gone
through multiple stages of clinical trials. As a result, a success-
ful immunotherapy is an intricate clinical procedure that affects
the function of a myriad of cells. Only comprehensive studies
that profile multiple aspects (e.g., cellular abundance, pheno-
types, and functions) over time at the finest details can effectively
monitor the convoluted immune response induced by therapy.
Many recent technical developments aim to provide a solution for
comprehensive clinical immune assessment.
In this book, we compiled a series of high-quality papers
that summarize recent developments of immune assessment tool
and methodology, as well as new biological findings in tumor
immunity and cancer immunotherapy.
The book starts with a number of reviews and research arti-
cles that form an update of cancer immunotherapy. Ma et al.
(1) reviewed new technologies to assess functional proteomics
of single immune cells, their applications in clinical cancer
immunotherapy, as well as new big-data computational methods
to interpret the massive readouts. Next, a review paper by Chen
et al. (2) highlighted recent advances in microfluidics tools used
for functional immunophenotyping and emphasized the poten-
tial of integrated microfluidics circuitry. Klinke (3) focused on the
concept of combining next-generation genome sequencing and
computational power to uncover mechanism underlying tumor
immunity evolution. In their opinion papers, Kwak et al. (4) and
Fan et al. (5) hypothesized the importance of protein secretion
profile in developing definitive correlates for cancer and immune
heterogeneity.
The book goes on to the discussion of biology behind can-
cer immunotherapy. Monjazeb et al. (6) explored the topic of
tumor induced immune suppression and proposed combinator-
ial therapy to induce antigen non-specific immune response and
overcome immune evasion. Najjar and Finke (7) reviewed the role
of myeloid derived suppressor cells (MDSC) in tumor mediated
immune evasion and updated the status of pre-clinical and clin-
ical tumor therapies designed for MDSC inhibition. Kawakami
et al. (8) suggested that using combinatory therapy that targets
shared immunosuppressive signaling pathway inhibitors to treat
cancer. Dobrzanski (9) summarized recently discovered functions
of CD4 T cell and new T cell lineages relevant to tumor immunity
and tumor progression. Finally, in a research article, Milano et al.
(10) showed pre-clinical evidence of nanocurcumin in improving
the efficacy of dendritic cell-based immunotherapy for esophageal
adenocarcinoma.
The editors thank all authors for their contributions and appre-
ciate the valuable discussions with our reviewers. We wish that this
special issue would serve as a reference book to the field and will
inspire more thoughts and discussions for future investigation.
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